A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer

Resistance to drugs targeting the androgen receptor (AR) signaling axis remains an important challenge in the treatment of prostate cancer patients. Activation of alternative growth pathways is one mechanism used by cancer cells to proliferate despite treatment, conferring drug resistance. Through a...

Descripción completa

Detalles Bibliográficos
Autores principales: Palit, Sander A. L., van Dorp, Jeroen, Vis, Daniel, Lieftink, Cor, Linder, Simon, Beijersbergen, Roderick, Bergman, Andries M., Zwart, Wilbert, van der Heijden, Michiel S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8249522/
https://www.ncbi.nlm.nih.gov/pubmed/34211036
http://dx.doi.org/10.1038/s41598-021-93107-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8249522/
https://www.ncbi.nlm.nih.gov/pubmed/34211036
http://dx.doi.org/10.1038/s41598-021-93107-w

Ejemplares similares